Evidence map›Paper›PMID 31009504›Full record

ArticlePloS one2019

Serum levels of CTRP3 in diabetic nephropathy and its relationship with insulin resistance and kidney function.

Nariman Moradi, Reza Fadaei, Mohammad Ebrahim Khamseh, Ali Nobakht, Mohammad Jafar Rezaei, Fereshteh Aliakbary, Akram Vatannejad, Jalil Hosseini

Abstract read
In one paragraph

Article in PloS one, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Plasma proteomics of acute tubular injury.Nature communications · 2024
    Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Decreased EpicardialInternational journal of molecular sciences · 2022
    Article
  11. Article
  12. Review
  13. Article
  14. Spinal muscular atrophy: Broad disease spectrum and sex-specific phenotypes.Biochimica et biophysica acta. Molecular basis of disease · 2021
    Review
  15. Observational
  16. Article
  17. Review
  18. Article
  19. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Nariman MoradiDepartment of Clinical Biochemistry, Faculty of Medicine, Kurdistan University of Medical Sciences, Sanandaj, Iran.
Reza FadaeiSleep Disorders Research Center, Kermanshah University of Medical Sciences, Kermanshah, Iran.
Mohammad Ebrahim KhamsehEndocrine Research Center, Institute of Endocrinology and Metabolism, Iran University of Medical Sciences, Tehran, Iran.
Ali NobakhtDepartment of Nephrology, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Mohammad Jafar RezaeiDepartment of Anatomy and Histology, Faculty of Medicine, Kurdistan University of Medical Sciences, Sanandaj, Iran.
Fereshteh AliakbaryInfertility and Reproductive Health Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Akram VatannejadDepartment of Comparative Bioscience, Faculty of Veterinary Medicine, University of Tehran, Tehran, Iran.
Jalil HosseiniInfertility and Reproductive Health Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundC1q TNF related protein 3 (CTRP3) is an adipokine secreted from adipose tissue. Previous studies have suggested that CTRP3 improves insulin sensitivity and reduces inflammation. Human studies have evaluated circulating levels of this adipokine in patients with diabetes mellitus (DM), diabetic retinopathy, metabolic syndrome, and coronary artery diseases. However, circulating levels of this adipokine in patients with diabetic nephropathy have not been evaluated. The present study aimed to assess serum levels of CTRP3 in patients with type 2 diabetes mellitus (T2DM) and diabetic nephropathy (T2DM-NP) and its relationship with metabolic and inflammatory markers.

methodsThis cross-sectional study was performed on 55 controls, 54 patients with T2DM, and 55 patients with T2DM-NP. Serum levels of CTRP3, adiponectin, TNF-α, and IL-6 were measured by ELISA technique.

resultsSerum levels of CTRP3 were significantly lower in patients with T2DM (257.61 ± 69.79 ng/mL, p < 0.001) and T2DM-NP (222.03 ± 51.99 ng/mL, p < 0.001) compared to controls (328.17 ± 80.73 ng/mL), and those with T2DM-NP compared to T2DM group. CTRP3 was independently associated with HOMA-IR (r = -0.327, p < 0.05) and adiponectin (r = 0.436, p < 0.01) in T2DM group. In T2DM-NP patients, CTRP3 independently was associated with eGFR (r = 0.428, p < 0.01) and HOMA-IR (r = -0.436, p < 0.01). Furthermore, CTRP3 revealed a ability to differentiate T2DM-NP patients from controls (area under curve (95% confidence interval): 0.881 (0.820-0.943) and p < 0.001).

conclusionDecreased serum levels of CTRP3 in patients with T2DM and diabetic nephropathy and its association with pathologic mechanism in these patients suggested a possible role for CTRP3 in pathogenesis of diabetic nephropathy; nevertheless, further studies are required in this regard.

Indexed as

Insulin ResistanceAdipokinesBiomarkersCross-Sectional StudiesDiabetes Mellitus, Type 2Diabetic NephropathiesFemaleHumansInflammationInterleukin-6MaleMetabolic SyndromeMiddle AgedTumor Necrosis Factor-alphaTumor Necrosis FactorsAdipokinesBiomarkersC1QTNF3 protein, humanInterleukin-6Tumor Necrosis Factor-alphaTumor Necrosis Factors

Identifiers

PMID31009504
PMCPMC6476508

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.